{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:02:46Z","timestamp":1783497766704,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cgh.2025.01.028","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:56:16Z","timestamp":1744174576000},"page":"2253-2262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biologic Switch Timing and Risk of Infection in Patients With Ulcerative Colitis\/Crohn\u2019s Disease: A Retrospective Study"],"prefix":"10.1016","volume":"23","author":[{"given":"Annie J.","family":"Kruger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Dormont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Capit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Schilsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wiekowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Bewtra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.01.028_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11894-019-0705-6","article-title":"Evolving Epidemiology of IBD","volume":"21","author":"Windsor","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.cgh.2025.01.028_bib2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.01.028_bib3","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s12325-022-02091-8","article-title":"Analysis of a real-world progression variable and related endpoints for patients with five different cancer types","volume":"39","author":"Torres","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.cgh.2025.01.028_bib4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.01.028_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn\u2019s disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.01.028_bib6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ecco-jcc\/jjaa177","article-title":"Effectiveness and safety of ustekinumab intensification at 90 mg every 4 weeks in Crohn\u2019s disease: a multicentre study","volume":"15","author":"Fumery","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.01.028_bib7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.01.028_bib8","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.01.028_bib9","first-page":"i211","article-title":"DOP75 Frequency and effectiveness of dose escalation of biologic therapy in inflammatory bowel disease: the RAINBOW-IBD study of ENEIDA","volume":"18","author":"Rub\u00edn De C\u00e9lix","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.01.028_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2010.04489.x","article-title":"Review article: explaining risks of inflammatory bowel disease therapy to patients","volume":"33","author":"Siegel","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.01.028_bib11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.01.028_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.01.028_bib13","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.01.028_bib15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/apt.16182","article-title":"Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease","volume":"53","author":"Dohos","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.01.028_bib16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cgh.2023.09.011","article-title":"Washout periods in inflammatory bowel disease trials: a systematic literature review and proposed solutions","volume":"22","author":"Wils","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.028_bib17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1177\/2050640619841538","article-title":"Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases","volume":"7","author":"Liefferinckx","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2025.01.028_bib19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.028_bib20","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.14309\/ajg.0000000000002398","article-title":"Long washout periods between biologics for inflammatory bowel disease clinical trials are unnecessary: a Canadian retrospective cohort study","volume":"118","author":"Vuyyuru","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.01.028_bib21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.gastro.2021.03.065","article-title":"Challenges and opportunities in IBD clinical trial design","volume":"161","author":"Dubinsky","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.01.028_bib22","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn\u2019s disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.028_bib23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.028_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.01.028_bib25","doi-asserted-by":"crossref","first-page":"i042","DOI":"10.1093\/ecco-jcc\/jjab232.035","volume":"16","author":"Sands","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.01.028_bib26","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2016.66","article-title":"Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease","volume":"111","author":"Yzet","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.01.028_bib27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/ibd\/izx110","article-title":"Combining anti-TNF-\u03b1 and vedolizumab in the treatment of inflammatory bowel disease: a case series","volume":"24","author":"Buer","year":"2018","journal-title":"Inflamm Bowel Dis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525002459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525002459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:39:59Z","timestamp":1777966799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525002459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1542356525002459"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.01.028","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic Switch Timing and Risk of Infection in Patients With Ulcerative Colitis\/Crohn\u2019s Disease: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}